REATA ALERT: Bragar Eagel & Squire, PC is investigating Reata Pharmaceuticals, Inc. on behalf of Reata shareholders and encourages investors to contact the company

NEW YORK–(COMMERCIAL THREAD) – Bragar Eagel & Squire, PC, a nationally recognized law firm, is investigating potential claims against Reata Pharmaceuticals, Inc. (“Reata” or the “Company”) (NASDAQ: RETA) on behalf of of Reata shareholders. Our investigation focuses on whether Reata has violated federal securities laws and / or engaged in other illegal business practices.

Click here to join the action.

On December 6, 2021, the United States Food and Drug Administration (“FDA”) released a backgrounder regarding Reata’s chronic kidney disease drug candidate, bardoxolone methyl. In it, the FDA said data submitted by Reata did not “demonstrate that bardoxolone is effective in slowing the loss of kidney function in patients with [Alport syndrome]. ”

Following this news, Reata’s share price fell $ 29.77 per share, or 37.8%, to close at $ 48.92 per share on December 6, 2021.

If you have purchased or acquired Reata shares and suffered a loss, are a long-time shareholder, have information, want to know more about these claims or have questions regarding this announcement or your rights or interests in respect of these claims. questions, please contact Brandon Walker or Alexandra B. Raymond by email at [email protected], by phone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation for you.

Comments are closed.